WAM: Fluticasone Superior to Montelukast for Initial Asthma Controller Therapy
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




WAM: Fluticasone Superior to Montelukast for Initial Asthma Controller Therapy

By W. A. Thomasson

Special to DG News

CHICAGO, IL -- July 16, 2001 -- Inhaled fluticasone (88 µg twice daily) has proved superior to oral montelukast (10 mg daily) on a variety of measures of asthma control.

This finding was presented at the World Asthma Meeting by Courtney Crim, MD, of GlaxoSmithKline in Research Triangle Park, North Carolina.

The data were from two identical studies that enrolled a total of 1055 patients who were inadequately controlled on short-acting beta-agonists but were not receiving controller therapy. Baseline FEV1(Forced expiratory volume at one second)- was 50-80 percent of predicted normal, with at least a 15 percent increase after albuterol use.

After 24 weeks, FEV1 had increased by 22.5 percent in fluticasone-treated patients and 14.2 percent in montelukast-treated patients; albuterol use had decreased 59.3 percent and 43.3 percent, respectively; and symptom scores had decreased by 51.1 percent and 31.7 percent. All differences are significant at the p=0.001 level, and differences in FEV1 were statistically significant at every two-week interval throughout the study. Differences in peak expiratory flow, nighttime awakenings, and symptom-free days were also significant.

There were likewise significantly more patients who identified themselves as "satisfied" with fluticasone therapy than with montelukast therapy - 84 percent versus 69 percent. In addition, 69 percent of physicians rated fluticasone "effective" or "very effective," while only 53 percent did so for montelukast.

Other papers presented at the meeting suggest that oral therapy may lead to significantly better compliance, especially in young patients, and may therefore offer "real world" advantages. These data, on the other hand, indicate that inhaled corticosteroids can offer inherently superior asthma control when compliance is good.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities